C, BSN, RN, illustrated the importance of consistent care to identify AEs like interstitial lung disease in patients with cancer.
Given the evolving role of trastuzumab deruxtecan (Enhertu) in the treatment of breast cancer, especially those who are HER2 ...
Dr Mohan engages with Nurse Goff, Dr Mann, and Nurse Brigle to explore effective multidisciplinary approaches for managing adverse events (AEs) associated with bispecific therapies and compares the AE ...
Key opinion leaders explores the management of gastrointestinal side effects in patients on osimertinib, focusing on ...
Key opinion leaders discusses strategies for handling gastrointestinal side effects in patients taking osimertinib, including ...
Medical experts compare the adverse event profile of lorlatinib to other ALK inhibitors like alectinib and brigatinib, ...
Medical experts discuss approaches to dose modifications and treatment interruptions for adverse events with ALK inhibitors, ...
January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.
Tislelizumab Plus Chemo Demonstrates Activity and Tolerability in Advanced Gastric/GEJ Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback